Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Study Overview

Pfizer has launched a phase 2/3 trial (NCT07363694) to test its drug PF-07275315 in adults with moderate to severe chronic obstructive pulmonary disease (COPD). The study aims to see if this new medicine can reduce flare-ups and improve day-to-day breathing and functioning in patients who remain symptomatic despite standard care. COPD is a large and growing market, so any new treatment that shows clear benefit could carry strong commercial value for Pfizer.

Intervention/Treatment

The treatment being tested is PF-07275315, given as a series of under-the-skin injections. Different dose levels will be studied against a placebo, which looks like the drug but has no active ingredient. The goal is to find a dose that offers better symptom control and fewer exacerbations while keeping side effects low.

Study Design

This is an interventional study where participants are randomly placed into different groups, each receiving either PF-07275315 or placebo in parallel. The trial is double-blind, meaning patients, doctors, and study staff who assess outcomes do not know who gets the real drug. A separate unblinded team gives the injections. The main purpose is treatment, not diagnosis or prevention, and the design is set up to provide clear, unbiased comparisons between the new drug and placebo.

Study Timeline

The study was first submitted and last updated on January 22, 2026, and is currently listed as not yet recruiting. The phase 2 portion is expected to follow patients for about 40 weeks, while the phase 3 portion will extend follow-up to about 68 weeks. Key future dates will include the primary completion date, when main results should be available, and the overall completion date, when full data, including longer-term safety, will be ready. These milestones will be important catalysts for investors tracking PFE.

Market Implications

This COPD program adds another mid- to late-stage asset to Pfizer’s pipeline at a time when the company is working to offset fading COVID-related revenue. If PF-07275315 shows strong results, it could open a new revenue stream in a chronic disease area currently dominated by companies such as GSK and AstraZeneca. In the near term, the listing of this phase 2/3 study supports the story of a rebuilding pipeline, which can help underpin investor confidence but is unlikely to move the stock on its own. As data readouts approach, volatility could rise for PFE and for peers in the respiratory space, as investors reassess market share expectations and long-term growth profiles.

The study is active as a planned, not-yet-recruiting trial, and further details are available on the ClinicalTrials.gov portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.